647 related articles for article (PubMed ID: 10609790)
1. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Haq R; Sawka CA; Franssen E; Berinstein NL
Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
[TBL] [Abstract][Full Text] [Related]
2. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Josting A; Rudolph C; Reiser M; Mapara M; Sieber M; Kirchner HH; Dörken B; Hossfeld DK; Diehl V; Engert A;
Ann Oncol; 2002 Oct; 13(10):1628-35. PubMed ID: 12377653
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
4. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma].
Li YH; Jiang WQ; Huang HQ; Zhang L; Liu DG; Xu RH; Zhou ZM; Sun XF; Lin TY; Xu GC; He YJ; Guang ZZ
Ai Zheng; 2002 Aug; 21(8):900-2. PubMed ID: 12478903
[TBL] [Abstract][Full Text] [Related]
6. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W
Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
[TBL] [Abstract][Full Text] [Related]
7. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Johnston LJ; Stockerl-Goldstein KE; Hu WW; Negrin RS; Hoppe RT; Blume KG; Horning SJ
Biol Blood Marrow Transplant; 2000; 6(5A):555-62. PubMed ID: 11071261
[TBL] [Abstract][Full Text] [Related]
8. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
9. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
Wang WS; Tzeng CH; Chiou TJ; Liu JH; Hsieh RK; Yen CC; Chen PM
Jpn J Clin Oncol; 1997 Jun; 27(3):154-7. PubMed ID: 9255269
[TBL] [Abstract][Full Text] [Related]
10. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
Bi J; Espina BM; Tulpule A; Boswell W; Levine AM
J Acquir Immune Defic Syndr; 2001 Dec; 28(5):416-21. PubMed ID: 11744828
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
12. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
Josting A; Sieniawski M; Glossmann JP; Staak O; Nogova L; Peters N; Mapara M; Dörken B; Ko Y; Metzner B; Kisro J; Diehl V; Engert A
Ann Oncol; 2005 Aug; 16(8):1359-65. PubMed ID: 15939712
[TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
14. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.
Tessoulin B; Thomare P; Delande E; Moynard J; Gastinne T; Moreau A; Bossard C; Mahé B; Blin N; Dubruille V; Touzeau C; Boudreault JS; Perrin F; Lok A; Guillaume T; Garnier A; Peterlin P; Gallas P; Chevallier P; Moreau P; Le Gouill S
Ann Hematol; 2017 Jun; 96(6):943-950. PubMed ID: 28374163
[TBL] [Abstract][Full Text] [Related]
17. Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma.
Buzzoni R; Colleoni M; Nelli P; Nolè F; Bajetta E
Leuk Lymphoma; 1994 Jun; 14(1-2):121-8. PubMed ID: 7920218
[TBL] [Abstract][Full Text] [Related]
18. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy.
Rapoport AP; Meisenberg B; Sarkodee-Adoo C; Fassas A; Frankel SR; Mookerjee B; Takebe N; Fenton R; Heyman M; Badros A; Kennedy A; Jacobs M; Hudes R; Ruehle K; Smith R; Kight L; Chambers S; MacFadden M; Cottler-Fox M; Chen T; Phillips G; Tricot G
Bone Marrow Transplant; 2002 Feb; 29(4):303-12. PubMed ID: 11896427
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Seymour JF; Grigg AP; Szer J; Fox RM
Cancer; 2002 Feb; 94(3):585-93. PubMed ID: 11857288
[TBL] [Abstract][Full Text] [Related]
20. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
